The CTD² Network and Cancer Systems Biology Consortium organized a virtual symposium series titled “Multidisciplinary Approaches to Understand Cancer Treatment Resistance”. Please join us on 11/16, 11/17, 12/2, 12/16, and 12/17. Click here to view the registration website.
Publications
644 Publications Available
Nature
CTD2 scientists at UCSF (1), Broad Institute, and TGen have identified that drug-tolerant persister cancer cells from multiple tumor types that survive chemotherapy were found to be vulnerable to chemical inhibition or genetic loss of function of GPX4.
Nature Genetics
UCSF (1) researchers identified genetic alterations that assist primary drivers, as co-drivers, that promote tumor growth and drug resistance in advanced-stage EGFR-mutant lung cancers.
Hepatology
Cancer Research
CTD2 scientists at UT MD Anderson Cancer Center developed a user-friendly bioinformatic resource, The Cancer Proteome Atlas (TCPA). This resource contains the expression levels of key cancer proteins (characterized by reverse-phase protein arrays) from patient tumors and cancer cell lines.
PLOS Computational Biology
Molecular Cell
Cell
CTD2 comprehensive molecular analysis of TCGA muscle-invasive (metastasis) bladder cases aid in subtyping and may inform optimal treatment options.